(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 112.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Syndax Pharmaceuticals's revenue in 2025 is $43,722,000.On average, 3 Wall Street analysts forecast SNDX's revenue for 2025 to be $11,495,594,997, with the lowest SNDX revenue forecast at $10,996,863,982, and the highest SNDX revenue forecast at $12,357,274,151. On average, 3 Wall Street analysts forecast SNDX's revenue for 2026 to be $21,301,046,000, with the lowest SNDX revenue forecast at $18,663,691,688, and the highest SNDX revenue forecast at $23,898,818,485.
In 2027, SNDX is forecast to generate $36,924,681,315 in revenue, with the lowest revenue forecast at $32,056,977,125 and the highest revenue forecast at $40,915,562,000.